Physiomics appoints biosimulation expert Claire Villette to technical team

Pharmaceutical solutions provider Physiomics on Monday expanded its technical team with the addition of Claire Villette, who joins as a Biosimulation scientist.

The AIM traded company described Villette as a biomedical computational scientist with six years of experience in multiscale modelling of biological tissue growth and completed her PhD in computational biomechanics at Imperial College London.

Jim Millen, chief executive of Physiomics, said: "As Physiomics continues to expand its client base we need talented young scientists to help us deliver the high-quality work our clients have become used to. I'm confident that Claire will be a great addition to the team"

During her studies, Villette was awarded an EPSRC Doctoral Prize fellowship to investigate new digital design optimisation techniques for tissue engineering scaffolds using machine learning algorithms.

She also completed a secondment at an Imperial College spin-out where she successfully developed a commercial software application for tailored tissue engineering.

Physiomics has developed a virtual tumour technology which aims to utilise computer modelling to predict the effects of various treatments in order to improve the success rate of drug discovery and development projects for a fraction of the time and cost normally expended on such research.

As of 1510 BST, Physiomics’ shares were down 1.19% at 4.15p.